Media Room
Fourth Quarter & Full Year 2025 Results
Fourth quarter and full year 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.
Press Releases
February 27, 2026
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
February 27, 2026
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
February 24, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
February 2026
Annual Report on Form 20-F
Annual Report on Form 20-F 2025
July 2025
Half-year Financial Reports
Half Year 2025 Financial Report
July 2025
Half-year Financial Reports
Half year 2025 financial report XBRL package
September 2024
Annual Report on Form 20-F
Annual Report on Form 20-F 2024